We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Angiotensin 1-7 (Ang-(1-7)) is a major active component of the renin-angiotensin system (RAS), produced from cleavage of Ang II by angiotensin-converting-enzyme type 2 (ACE2). Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity.
CAT No: R1805
CAS No: 51833-78-4
Synonyms/Alias: Angiotensin (1-7);51833-78-4;angiotensin 1-7;ASP-ARG-VAL-TYR-ILE-HIS-PRO;TXA127;Angiotensin i (1-7);angiotensin-(1-7);Angiotensin II (1-7) heptapeptide;angiotensin II (1-7);8-Des-phe-angiotensin II;Ang-(1-7);TXA-127;Human angiotensin-(1-7);1-7-Human angiotensin II;Sh-heptapeptide-13;Bf-angiotensin 1-7;TXA 127;IJ3FUK8MOF;ang 1-7;MFCD00153513;39386-80-6;Angiotensin peptide (1-7);5-ile-angiotensin-(1-7);Human angiotensin ii (1-7);CHEBI:55438;Ile(5)-angiotensin II (1-7);Angiotensin II, 5-L-isoleucine-8-de-L-phenylalanine-;Angiotensin I/II (1-7) trifluoroacetate salt;(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid;Angiotensin (1-7) xTFA salt;L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline;L-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline;(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid;angiotensin-I (1-7);UNII-IJ3FUK8MOF;Angiotensin, Canine, Rat;Ang I (1-7);Angiotensin II, des-phe(8)-;(2S)-1-((2S)-2-(((2S,3S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-amino-4-hydroxy-4-oxobutanoyl)amino)-5-(diaminomethylideneamino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylpentanoyl)amino)-3-(3H-imidazol-4-yl)propanoyl)pyrrolidine-2-carboxylic acid;Ang-1-7 acetate;Angiotensin(1-7);DRVYIHP;Angiotensin II, des-phenylalanine(8)-;Angiotensin i/ii(1-7);Talfirastide (USAN/INN);GTPL582;Ang(1-7);GTPL5578;Therapeutic Angiotensin-(1-7);ANGIOTENSIN 1-7 ACETATE;CHEMBL3545347;SCHEMBL15926158;SCHEMBL25354851;BDBM85556;PVHLMTREZMEJCG-GDTLVBQBSA-N;[125I]ang-(1-7);GLXC-15146;ANGIOTENSIN 1-7 [WHO-DD];EX-A7295;SH-HEPTAPEPTIDE-13 [INCI];TXA127; Ang-(1-7);AKOS024456667;AKOS040759110;CS-3413;DB11720;Angiotensin (1-7) acetate salt hydrate;Angiotensin II, 8-de-L-phenylalanine-;NCGC00167219-01;AS-76407;DA-70861;FA108515;HY-12403;NS00073118;1-7-ANGIOTENSIN II, 5-L-ISOLEUCINE-;D12942;F85068;[125I]angiotensin-(1-7) (human, mouse, rat);BRD-K36040345-001-01-1;BRD-K36040345-001-02-9;Q27074464;(2S)-1-[(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-AMINO-3-CARBOXYPROPANAMIDO]-5-CARBAMIMIDAMIDOPENTANAMIDO]-3-METHYLBUTANAMIDO]-3-(4-HYDROXYPHENYL)PROPANAMIDO]-3-METHYLPENTANAMIDO]-3-(1H-IMIDAZOL-4-YL)PROPANOYL]PYRROLIDINE-2-CARBOXYLIC ACID;(S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-1-amino-6-((S)-2-amino-3-carboxypropanamido)-15-sec-butyl-12-(4-hydroxybenzyl)-1-imino-9-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecane)pyrrolidine-2-carboxylic acid;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C41H62N12O11 |
M.W/Mr. | 899 |
Sequence | One Letter Code:DRVYIHP Three Letter Code:H-Asp-Arg-Val-Tyr-Ile-His-Pro-OH |
Biological Activity | Endogenous peptide fragment. Induces vasorelaxation through release of NO and prostaglandins, perhaps through activation of a non-AT1, non-AT2 receptor, Mas. Counteracts the vasoconstrictive and proliferative effects of angiotensin II and stimulates vasopressin (anti-diuretic hormone) release in vivo. |
Source# | Synthetic |
Length | 7 |
Long-term Storage Conditions | Soluble to 1 mg/ml in water |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1 |
InChI Key | PVHLMTREZMEJCG-GDTLVBQBSA-N |
2. The spatiotemporal control of signalling and trafficking of the GLP-1R
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.